(VIANEWS) – Shares of TherapeuticsMD (NASDAQ: TXMD) slid by a staggering 31.44% in 21 sessions from $6.17 at 2022-11-10, to $4.23 at 19:43 EST on Monday, after two sequential sessions in a row of gains. NASDAQ is dropping 1.58% to $11,049.50, after two consecutive sessions in a row of losses.

TherapeuticsMD’s last close was $4.46, 88.42% below its 52-week high of $38.50.

About TherapeuticsMD

TherapeuticsMD, Inc. is a United States women’s health company. The company provides IMVEXXY, a treatment for moderate-to severe dyspareunia, and BIJUVA which is a bioidentical hormonal therapy combination of 17ss -estradiol, and progesterone to treat moderate-to–severe vasomotor conditions. TX-015HR is a transdermal progesterone cream. TX006HR is an estradiol-progesterone cream. TX007HR and TX008HR are candidates for transdermal patches. TX009HR is an oral progesterone/estradiol formula. The company also produces and distributes generic and branded prescription prenatal vitamins, under the vitaTrue and vitaMedMD brands. It sells prescription drugs and prenatal vitamins to retail pharmacie distributors as well wholesale distributors. TherapeuticsMD, Inc., was established in Boca Raton, Florida in 2008.

Earnings Per Share

As for profitability, TherapeuticsMD has a trailing twelve months EPS of $-0.666.

More news about TherapeuticsMD (TXMD).